Ascendis Pharma A/S (NASDAQ:ASND) Insider Sells $4,641,015.40 in Stock

Ascendis Pharma A/S (NASDAQ:ASND) insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ascendis Pharma A/S Trading Down 0.4%

Ascendis Pharma A/S stock traded down $1.02 during mid-day trading on Tuesday, hitting $237.65. 875,179 shares of the stock were exchanged, compared to its average volume of 710,797. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12 month low of $150.89 and a 12 month high of $250.74. The firm’s fifty day simple moving average is $231.95 and its two-hundred day simple moving average is $219.49. The stock has a market capitalization of $14.82 billion, a price-to-earnings ratio of 27.41 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. Analysts forecast that Ascendis Pharma A/S will post 5.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ASND. The Goldman Sachs Group restated a “buy” rating and set a $255.00 price target on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday. Barclays raised their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a research note on Thursday, April 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $291.50.

Institutional Trading of Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC bought a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $26,000. Arax Advisory Partners increased its stake in Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares in the last quarter. Leonteq Securities AG bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Ascendis Pharma A/S during the 4th quarter valued at $42,000. Finally, Jones Financial Companies Lllp boosted its holdings in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.